Phase 1b/2, Open-Label Dose Escalation With Expansion Study Of A ACTIVE Investigational Product In Adult Subjects With Relapsed/Refractory Primary Or Secondary Central Nervous System Lymphoma, Followed By A Phase 2 Open-Label Single Dose Level Study Of The Study Drug In Adult Subjects With Relapsed/Refractory Primary Central Nervous System Lymphoma. Read more
Treatment Of Actively Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) And Relapsed Favorable Histology Wilms Tumors (FHWT) Read more
A Phase 2 Study Of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation In Actively-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) Read more
A Phase 1 And 2a Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity And Antitumor Activity Of LAVA-051 In Patients With Relapsed Or Refractory CD1d-Positive Chronic Lymphocytic Leukemia, Multiple Myeloma Or Acute Myeloid Leukemia Read more
A Phase 1 / 2 Study To Evaluate The Safety And Tolerability Of Adoptively Transferred Autologous T Cells In Patients With Relapsed Refractory Multiple Myeloma Read more
Safety Of Switching From Intravenous Daratumumab To Subcutaneous Daratumumab In Patients With Multiple Myeloma Read more
Phase II Trial Of SMO/AKT/NF2 Inhibitors In Progressive Meningiomas With SMO/AKT/NF2 Mutations Read more
A Randomized, Multicenter, Phase 2 Study Of DSP-7888 Dosing Emulsion In Combination With Bevacizumab Versus Bevacizumab Alone In Patients With Recurrent Or Progressive Glioblastoma Following Initial Therapy Read more
